Phase 3
N=608
Study of Cemiplimab in Adults With Cervical Cancer
Squamous Cell Carcinoma (SCC) · Recurrent or Metastatic, Platinum-refractory Cervical Cancer
Bottom Line
View on ClinicalTrials.gov: NCT03257267 ↗Enrolled (actual)
608
Serious AEs
30.9%
Results posted
Apr 2022
Primary outcome: Primary: Overall Survival (OS) — 11.7; 8.5 Months — p=<0.00001
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Cemiplimab (Drug); Investigator Choice (IC) Chemotherapy (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- Female
- Sponsor
- Regeneron Pharmaceuticals
- Primary completion
- Mar 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Overall Survival (OS) |
11.7; 8.5 | <0.00001 sig |
| PRIMARY Overall Survival (OS) in the SCC Population |
10.9; 8.8 | 0.00024 sig |
| SECONDARY Progression-free Survival (PFS) Assessed by Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST 1.1) |
2.8; 2.9 | 0.00031 sig |
| SECONDARY Objective Response Rate (ORR) Assessed by Investigator Using RECIST 1.1 |
52; 19 | 0.00002 sig |
| SECONDARY Duration of Response (DOR) Assessed Per RECIST 1.1 |
18.7; 7.2 | — |
| SECONDARY Quality of Life (QoL): Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) of Global Health Status /Quality of Life (GHS/QoL) and Physical Functioning Scales |
0.46; -8.54; -0.27; -8.86 | — |
| SECONDARY Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Death |
269; 266; 96; 78; 5; 2 | — |
| SECONDARY Number of Participants With New or Worsened Laboratory Results by National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE) Grade |
84; 137; 47; 32; 12; 10 | — |
Summary
The primary objective is to compare overall survival (OS) for patients with recurrent or metastatic cervical cancer who have histology of squamous cell carcinoma (SCC) and who have any eligible histology treated with either cemiplimab or investigator's choice (IC) chemotherapy.
The secondary objectives performed among SCC patients and among all eligible histologies (SCC and adenocarcinoma/adenosquamous carcinoma (AC) are:
* To compare progression-free survival (PFS) of cemiplimab versus IC chemotherapy
* To compare objective response rate (ORR) (partial response [PR] + complete response [CR]) of cemiplimab versus IC chemotherapy per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
* To compare the duration of response (DOR) of cemiplimab versus IC chemotherapy
* To compare the safety profiles of cemiplimab versus IC chemotherapy by describing adverse events (AE)
* To compare quality of life (QOL) for patients treated with cemiplimab versus IC chemotherapy using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Eligibility Criteria
The criteria listed below are not intended to contain all considerations relevant to a patient's potential participation in this clinical trial.
Key Inclusion Criteria
- Recurrent, persistent, and/or metastatic cervical cancer with squamous cell histology, for which there is not a curative-intent option (surgery or radiation therapy with or without chemotherapy).
- Acceptable histologies (squamous carcinoma, adenocarcinoma, and adenosquamous carcinoma) as defined in the protocol
- Tumor progression or recurrence after treatment with platinum therapy (must have been used to treat metastatic, persistent, or recurrent cervical cancer)
- Patient must have measurable disease as defined by RECIST 1.1.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤1
- ≥18 years old
- Adequate organ or bone marrow function
- Received prior bevacizumab therapy or had clinically documented reason why not administered
- Received prior paclitaxel therapy or had clinically documented reason why not administered
Key Exclusion Criteria
- Ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments
- Prior treatment with an agent that blocks the PD-1/PD-L1 pathway
- Prior treatment with other systemic immune-modulating agents that was
- within fewer than 4 weeks (28 days) of the enrollment date, or
- associated with irAEs of any grade within 90 days prior to enrollment, or
- associated with toxicity that resulted in discontinuation of the immune modulating agent
- Active or untreated brain metastases
- Immunosuppressive corticosteroid doses (>10 mg prednisone daily or equivalent) within 4 weeks prior to the first dose of study drug cemiplimab or IC chemo)
- Active infection requiring therapy
- History of pneumonitis within the last 5 years
- History of documented allergic reactions or acute hypersensitivity reaction attributed to antibody treatments
- Concurrent malignancy other than cervical cancer and/or history of malignancy other than cervical cancer within 3 years of date of first planned dose of study drug cemiplimab or IC chemo), except for tumors with negligible risk of metastasis or death, such as adequately treated cutaneous squamous cell carcinoma or basal cell carcinoma of the skin or ductal carcinoma in situ of the breast. Patients with hematologic malignancies (eg, chronic lymphocytic leukemia) are excluded.
Note: Other protocol defined Inclusion/Exclusion apply
Data sourced from ClinicalTrials.gov (NCT03257267). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.